Interchangeability of Biosimilars: Overcoming the Final Hurdles

被引：14
作者：
Barbier, Liese [1 ]
Vulto, Arnold G. [1 ,2 ]
机构：
[1] Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, B-3000 Leuven, Belgium
[2] Erasmus Univ, Med Ctr, Dept Hosp Pharm, Rotterdam, Netherlands
来源：
DRUGS | 2021年 / 81卷 / 16期
关键词：
INFLIXIMAB; IMMUNOGENICITY; ANTIBODIES; SCIENCE; CT-P13;
D O I：
10.1007/s40265-021-01629-4
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：1897 / 1903
页数：7
相关论文
共 24 条
[1]  
[Anonymous], 2017, BIOS EU INF GUID HEA
[2]  
Barbier L, 2019, VALUE HEALTH, V22, pS786
[3]   European Stakeholder Learnings Regarding Biosimilars: Part II-Improving Biosimilar Use in Clinical Practice [J].
Barbier, Liese ;
Simoens, Steven ;
Vulto, Arnold G. ;
Huys, Isabelle .
BIODRUGS, 2020, 34 (06) :797-808
[4]   The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review [J].
Barbier, Liese ;
Ebbers, Hans C. ;
Declerck, Paul ;
Simoens, Steven ;
Vulto, Arnold G. ;
Huys, Isabelle .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 108 (04) :734-755
[5]   Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars [J].
Begona Ruiz-Arguello, M. ;
Maguregui, Ainara ;
Ruiz del Agua, Ainhoa ;
Pascual-Salcedo, Dora ;
Martinez-Feito, Ana ;
Jurado, Teresa ;
Plasencia, Chamaida ;
Balsa, Alejandro ;
Llinares-Tello, Francisca ;
Rosas, Jose ;
Torres, Nerea ;
Martinez, Antonio ;
Nagore, Daniel .
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (09) :1693-1696
[6]   Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima [J].
Ben-Horin, Shomron ;
Yavzori, Miri ;
Benhar, Itai ;
Fudim, Ella ;
Picard, Orit ;
Ungar, Bella ;
Lee, SooYoung ;
Kim, SungHwan ;
Eliakim, Rami ;
Chowers, Yehuda .
GUT, 2016, 65 (07) :1132-1138
[7]   The Importance of Countering Biosimilar Disparagement and Misinformation [J].
Cohen, Hillel P. ;
McCabe, Dorothy .
BIODRUGS, 2020, 34 (04) :407-414
[8]   Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price! [J].
Dutta, Binita ;
Huys, Isabelle ;
Vulto, Arnold G. ;
Simoens, Steven .
BIODRUGS, 2020, 34 (02) :159-170
[9]   Are we ready to close the discussion on the interchangeability of biosimilars? [J].
Ebbers, Hans C. ;
Schellekens, Huub .
DRUG DISCOVERY TODAY, 2019, 24 (10) :1963-1967
[10]   Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease [J].
Fiorino, Gionata ;
Begona Ruiz-Arguello, M. ;
Maguregui, Ainara ;
Nagore, Daniel ;
Correale, Carmen ;
Radice, Simona ;
Gilardi, Daniela ;
Allocca, Mariangela ;
Furfaro, Federica ;
Martinez, Antonio ;
Danese, Silvio .
INFLAMMATORY BOWEL DISEASES, 2018, 24 (03) :601-606
123